Warning: The NCBI web site requires JavaScript to function. more...
Generate a file for use with external citation management software.
Malignant melanoma, breast cancer and other cancers in patients with Parkinson's disease.
Rugbjerg K, Friis S, Lassen CF, Ritz B, Olsen JH.
Int J Cancer. 2012 Jan 25. doi: 10.1002/ijc.27443. [Epub ahead of print]
Related citations
Cyclooxygenase-2 inhibition causes antiangiogenic effects on tumor endothelial and vascular progenitor cells.
Muraki C, Ohga N, Hida Y, Nishihara H, Kato Y, Tsuchiya K, Matsuda K, Totsuka Y, Shindoh M, Hida K.
Int J Cancer. 2012 Jan 1;130(1):59-70. doi: 10.1002/ijc.25976. Epub 2011 Apr 20.
MC1R genotypes and risk of melanoma before age 40 years: A population-based case-control-family study.
Cust AE, Goumas C, Holland EA, Agha-Hamilton C, Aitken JF, Armstrong BK, Giles GG, Kefford RF, Schmid H, Hopper JL, Mann GJ, Jenkins MA.
Int J Cancer. 2012 Aug 1;131(3):E269-81. doi: 10.1002/ijc.27357. Epub 2012 Jan 30.
The metastatic microenvironment: Brain-residing melanoma metastasis and dormant micrometastasis.
Izraely S, Sagi-Assif O, Klein A, Meshel T, Tsarfaty G, Pasmanik-Chor M, Nahmias C, Couraud PO, Ateh E, Bryant JL, Hoon DS, Witz IP.
Int J Cancer. 2011 Oct 25. doi: 10.1002/ijc.27324. [Epub ahead of print]
Function but not phenotype of melanoma peptide-specific CD8(+) T cells correlate with survival in a multiepitope peptide vaccine trial (ECOG 1696).
Schaefer C, Butterfield LH, Lee S, Kim GG, Visus C, Albers A, Kirkwood JM, Whiteside TL.
Int J Cancer. 2011 Oct 24. doi: 10.1002/ijc.26481. [Epub ahead of print]
Association of activated c-Met with NRAS-mutated human melanomas.
Chattopadhyay C, Ellerhorst JA, Ekmekcioglu S, Greene VR, Davies MA, Grimm EA.
Int J Cancer. 2012 Jul 15;131(2):E56-65. doi: 10.1002/ijc.26487. Epub 2012 Jan 11.
PRKX, TTBK2 and RSK4 expression causes sunitinib resistance in kidney carcinoma- and melanoma-cell lines.
Bender C, Ullrich A.
Int J Cancer. 2012 Jul 15;131(2):E45-55. doi: 10.1002/ijc.26486. Epub 2012 Feb 28.
Regression of melanoma metastases after immunotherapy is associated with activation of antigen presentation and interferon-mediated rejection genes.
Carretero R, Wang E, Rodriguez AI, Reinboth J, Ascierto ML, Engle AM, Liu H, Camacho FM, Marincola FM, Garrido F, Cabrera T.
Int J Cancer. 2012 Jul 15;131(2):387-95. doi: 10.1002/ijc.26471. Epub 2011 Nov 9.
Glycosaminoglycan mimicry by COAM reduces melanoma growth through chemokine induction and function.
Piccard H, Berghmans N, Korpos E, Dillen C, Aelst IV, Li S, Martens E, Liekens S, Noppen S, Damme JV, Sorokin L, Opdenakker G.
Int J Cancer. 2011 Sep 27. doi: 10.1002/ijc.26465. [Epub ahead of print]
The role of melanoma tumor-derived nitric oxide in the tumor inflammatory microenvironment: Its impact on the chemokine expression profile, including suppression of CXCL10.
Tanese K, Grimm EA, Ekmekcioglu S.
Int J Cancer. 2011 Sep 22. doi: 10.1002/ijc.26451. [Epub ahead of print]
Differential effects of the glycolysis inhibitor 2-deoxy-D-glucose on the activity of pro-apoptotic agents in metastatic melanoma cells, and induction of a cytoprotective autophagic response.
Giammarioli AM, Gambardella L, Barbati C, Pietraforte D, Tinari A, Alberton M, Gnessi L, Griffin RJ, Minetti M, Malorni W.
Int J Cancer. 2011 Sep 12. doi: 10.1002/ijc.26420. [Epub ahead of print]
A prospective, population-based study of 40,000 women regarding host factors, UV exposure and sunbed use in relation to risk and anatomic site of cutaneous melanoma.
Nielsen K, Måsbäck A, Olsson H, Ingvar C.
Int J Cancer. 2012 Aug 1;131(3):706-15. doi: 10.1002/ijc.26408. Epub 2011 Oct 20.
Autophagy-mediated chemosensitization by cysteamine in cancer cells.
Wan XM, Zheng F, Zhang L, Miao YY, Man N, Wen LP.
Int J Cancer. 2011 Sep 1;129(5):1087-95. doi: 10.1002/ijc.25771. Epub 2011 Mar 25.
Inhibition of neutrophil infiltration into A549 lung tumors in vitro and in vivo using a CXCR2-specific antagonist is associated with reduced tumor growth.
Tazzyman S, Barry ST, Ashton S, Wood P, Blakey D, Lewis CE, Murdoch C.
Int J Cancer. 2011 Aug 15;129(4):847-58. doi: 10.1002/ijc.25987. Epub 2011 Apr 13.
Relationship between sunbed use and melanoma risk in a large case-control study in the United Kingdom.
Elliott F, Suppa M, Chan M, Leake S, Karpavicius B, Haynes S, Barrett JH, Bishop DT, Newton-Bishop JA.
Int J Cancer. 2012 Jun 15;130(12):3011-3. doi: 10.1002/ijc.26347. Epub 2011 Aug 30. No abstract available.
Epigenetic regulation by decitabine of melanoma differentiation in vitro and in vivo.
Alcazar O, Achberger S, Aldrich W, Hu Z, Negrotto S, Saunthararajah Y, Triozzi P.
Int J Cancer. 2012 Jul 1;131(1):18-29. doi: 10.1002/ijc.26320. Epub 2011 Sep 6.
The tumor microenvironment expression of p-STAT3 influences the efficacy of cyclophosphamide with WP1066 in murine melanoma models.
Hatiboglu MA, Kong LY, Wei J, Wang Y, McEnery KA, Fuller GN, Qiao W, Davies MA, Priebe W, Heimberger AB.
Int J Cancer. 2012 Jul 1;131(1):8-17. doi: 10.1002/ijc.26307. Epub 2011 Aug 24.
Tumor eradication by immunotherapy with biodegradable PLGA microspheres--an alternative to incomplete Freund's adjuvant.
Mueller M, Schlosser E, Gander B, Groettrup M.
Int J Cancer. 2011 Jul 15;129(2):407-16. doi: 10.1002/ijc.25914. Epub 2011 Mar 28.
ETS-1/RhoC signaling regulates the transcription factor c-Jun in melanoma.
Spangler B, Kappelmann M, Schittek B, Meierjohann S, Vardimon L, Bosserhoff AK, Kuphal S.
Int J Cancer. 2012 Jun 15;130(12):2801-11. doi: 10.1002/ijc.26277. Epub 2011 Aug 12.
Genetic variants in DNA repair genes and the risk of cutaneous malignant melanoma in melanoma-prone families with/without CDKN2A mutations.
Liang XS, Pfeiffer RM, Wheeler W, Maeder D, Burdette L, Yeager M, Chanock S, Tucker MA, Goldstein AM, Yang XR.
Int J Cancer. 2012 May 1;130(9):2062-6. doi: 10.1002/ijc.26231. Epub 2011 Aug 9.
Filters: Manage Filters
Your browsing activity is empty.
Activity recording is turned off.
Turn recording back on